Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619983 · ClinicalTrials.gov registry record · Phase 4
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
A Phase 4 study, sponsored by Wake Forest University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT00619983 is a Phase 4 study that was terminated before completion, run by Wake Forest University. The registered enrollment target is 22 participants.
The verdict
NCT00619983, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the combination of the the three drugs gabapentin, duloxetine, and donepezil are effective in treating pain in people with diabetic neuropathy or patients with failed low back syndrome (chronic back pain).
Interventions
- DRUG placebo
- DRUG duloxetine
- DRUG gabapentin
- DRUG donepezil
- DRUG donepezil 2.5 mg and duloxetine 30mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619983
The ClinicalTrials.gov registry entry for NCT00619983 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT00619983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619983 about?
NCT00619983 is a clinical study titled "Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy". The purpose of the study is to determine whether the combination of the the three drugs gabapentin, duloxetine, and donepezil are effective in treating pain in people with diabetic neuropathy or patients with failed low back syndrome (chronic back pain).
What is the current status of trial NCT00619983?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2008-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00619983?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG), gabapentin (DRUG), donepezil (DRUG), donepezil 2.5 mg and duloxetine 30mg (DRUG).
Who is sponsoring clinical trial NCT00619983?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.